KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tenet Healthcare (THC) EBIT (2016 - 2025)

Historic EBIT for Tenet Healthcare (THC) over the last 17 years, with Q4 2025 value amounting to $853.0 million.

  • Tenet Healthcare's EBIT rose 389.77% to $853.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $3.5 billion, marking a year-over-year decrease of 4110.14%. This contributed to the annual value of $3.5 billion for FY2025, which is 4110.14% down from last year.
  • Latest data reveals that Tenet Healthcare reported EBIT of $853.0 million as of Q4 2025, which was up 389.77% from $889.0 million recorded in Q3 2025.
  • In the past 5 years, Tenet Healthcare's EBIT ranged from a high of $3.3 billion in Q1 2024 and a low of $520.0 million during Q1 2021
  • Over the past 5 years, Tenet Healthcare's median EBIT value was $743.0 million (recorded in 2021), while the average stood at $858.9 million.
  • Its EBIT has fluctuated over the past 5 years, first skyrocketed by 44477.61% in 2024, then plummeted by 7129.38% in 2025.
  • Quarter analysis of 5 years shows Tenet Healthcare's EBIT stood at $751.0 million in 2021, then dropped by 28.63% to $536.0 million in 2022, then surged by 37.13% to $735.0 million in 2023, then rose by 11.7% to $821.0 million in 2024, then grew by 3.9% to $853.0 million in 2025.
  • Its EBIT stands at $853.0 million for Q4 2025, versus $889.0 million for Q3 2025 and $823.0 million for Q2 2025.